Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

No association found between CYP2D6 genotype and early breast cancer events in tamoxifen-treated patients.

Acta oncologica (Stockholm, Sweden) - 1 Feb 2014

Markkula Andrea, Hjertberg Maria, Rose Carsten, Ingvar Christian, Jernström Helena

Abstract excerpt

BACKGROUND: CYP2D6 is considered the key enzyme in tamoxifen metabolism. Several studies have investigated the relationship between the CYP2D6 genotype and tamoxifen treatment outcome, with discrepant results. CYP2D6 inhibitor use, aromatase inhibitor use, and chemotherapy may account for some of the discrepancies. We examined the association between CYP2D6 genotype and early breast cancer events in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP2D6
Share to Antineoplastic Agents, Hormonal

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Disease-Free Survival

Share to Kaplan-Meier Estimate

Share to Proportional Hazards Models

Share to Sweden

Share to Tamoxifen

Source

Identifiers

PMID: 24125101
DOI: 10.3109/0284186X.2013.840739

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

No association found between CYP2D6 genotype and early breast cancer events in tamoxifen-treated patients.PMID 24125101Read ↗

Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment.Semantic proximity Read ↗

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.Semantic proximity Read ↗

CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8.Semantic proximity Read ↗

CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.Semantic proximity Read ↗

CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines.Semantic proximity Read ↗

Impact of CYP2D6 polymorphism on tamoxifen therapy: where are we?Semantic proximity Read ↗

Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer.Semantic proximity Read ↗

Early increase in tamoxifen dose in CYP2D6 poor metaboliser breast cancer patients and survival: A propensity score matching analysis.Semantic proximity Read ↗

Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment.Semantic proximity Read ↗

CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial.Semantic proximity Read ↗

CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study.Semantic proximity Read ↗

Association between genetic polymorphisms of CYP2D6 and outcomes in breast cancer patients with tamoxifen treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.